Bactericidal effects of amoxyciffin/clavulanic acid against a <i>Legionella pneumophila</i> pneumonia in the weanling rat

Smith, G. M.; Abbott, K. H.; Wilkinson, M. J.; Beale, A S; Sutherland, Robert L.

doi:10.1093/jac/27.1.127

Cited by 14 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these studies, neither amoxicillin nor ticarcillin alone showed activity against cell-associated organisms. Furthermore, in an animal model, the combination of clavulanate with either amoxicillin or ticarcillin proved comparable to erythromycin in eradication of organisms within pulmonary alveolar macrophages (13,14). A small but significant advantage was noted for the combination of ticarcillin with clavulanic acid compared with clavulanate alone (13).…”

mentioning

confidence: 97%

“…Several P-lactam antibiotics actually demonstrate activity against Legionella spp. in vitro on various media (9,11), but a number of these are ineffective when examined against intracellular Legionella strains in vitro or in animal models of infection with these organisms (3,13,14,16). A notable exception to these observations is the fact that both clavulanic acid alone and combinations of this agent with either amoxicillin or ticarcillin have demonstrated activity against cell-associated Legionella pneumophila in vitro and in experimental animal models (13,14,16).…”

mentioning

confidence: 99%

“…Both in tissue culture (16) and in a weanling rat model of infection (13,14), clavulanic acid has proven effective in reducing numbers of intracellular L. pneumophila organisms. In these studies, neither amoxicillin nor ticarcillin alone showed activity against cell-associated organisms.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp

Collins

Wennersten

Ferraro

et al. 1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 97%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp

Collins

Wennersten

Ferraro

et al. 1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…L. pneumophila 1624, serogroup 1, a ,-lactamase-producing clinical isolate (supplied by Julian Dennis, Porton Down, Wiltshire, England) was used in tissue culture studies in vitro (16) and in in vivo studies with immunocompetent rats (13). A control strain, L. pneumo-* Corresponding author.…”

Section: Methodsmentioning

confidence: 99%

“…In addition, synergy has been demonstrated between P-lactams and clavulanic acid in vitro (8,10), and both the inhibitor and the combination of amoxicillin and clavulanic acid have been shown to produce bactericidal effects against intracellular L. pneumophila in tissue culture studies in vitro (17) and in immunocompetent rats (13).…”

mentioning

confidence: 99%

Bactericidal effects of ticarcillin-clavulanic acid against Legionella pneumophila pneumonia in immunocompromised weanling rats

Smith¹,

Abbott²,

Wilkinson³

et al. 1991

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A model of acute LegioneUla pneumophila pneumonia in neutropenic weanling rats was developed as a means of assessing the efficacies in vivo of the ,I-lactams ticarcillin, ticarcillin-clavulanic acid, and clavulanic acid, agents active against the organism in vitro. Weanling rats were dosed with cyclophosphamide 3 days before and immediately prior to infection by intrabronchial intubation with L. pneumophila. The bacteria persisted in the lungs of untreated animals at high counts (5.0 to 7.0 loglo CFU/g of lung tissue) for up to 168 h after infection, and the histological characteristics of the infection were similar to those of the disease in humans. Transmission electron micrography revealed the presence of L. pneumophila multiplying within alveolar macrophages. Therapy with ticarcillin was ineffective in reducing the bacterial numbers in the lung tissue, whereas ticarcillinclavulanic acid and clavulanic acid were active, producing bactericidal effects similar to those of erythromycin. The ticarcillin-clavulanic acid combination was significantly more efficacious (P < 0.01) than corresponding doses of clavulanic acid alone. Synergistic activity between ticarciflin and clavulanic acid against L. pneumophila has been demonstrated in vivo, and the combination showed activity similar to that of erythromycin.The 1-lactamase inhibitor clavulanic acid displays only a low order of antibacterial activity against most pathogenic bacteria, but an exception is Legionella pneumophila, which is susceptible to low concentrations of the compound (16). In addition, synergy has been demonstrated between P-lactams and clavulanic acid in vitro (8, 10), and both the inhibitor and the combination of amoxicillin and clavulanic acid have been shown to produce bactericidal effects against intracellular L. pneumophila in tissue culture studies in vitro (17) and in immunocompetent rats (13).These findings suggested that studies with antibiotics against experimental L. pneumophila infections were warranted, but initial studies with clavulanic acid combinations showed that the conventional guinea pig model of legionellosis was unsuitable for this purpose because of the sensitivity of this animal species to P-lactam antibiotics. For this reason, we have developed an experimental model of L. pneumophila pneumonia with neutropenic weanling rats, suitable for the evaluation of ,-lactams and other agents.The studies reported here were designed to investigate the activity of clavulanic acid and the combination of ticarcillin plus clavulanic acid against L. pneumophila in vitro and in the neutropenic rat model of legionellosis. In vitro susceptibility tests. MICs were determined by serial dilution of the compounds into buffered charcoal-yeast extract agar (Oxoid) (1). Inocula were prepared by harvesting growth of L. pneumophila on agar plates after 72 h of incubation into 1 ml of Mueller-Hinton broth (BBL) and adjusting the turbidity to that of a 0.5 McFarland barium sulphate turbidity standard. Volumes (0.003 ml) were inoculated onto each plate,...

show abstract

FatalLegionella pneumophila pneumonia: Treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy

1992

View full text Add to dashboard Cite

A 68-year-old male, having just returned from a two-week holiday on the Island of Ischia, developed unilateral pneumonia for which he was treated with oral amoxicillin-clavulanic acid and hospitalized within three days when the disease worsened and spread to both lungs. Despite parenteral amoxicillin-clavulanic acid (up to 2.2 g i.v. t.i.d.) the pneumonia spread rapidly over the next three days. Sputum cultures returned post mortem yielded Legionella pneumophila serogroup 1 and urine tests revealed the presence of Legionella antigen. Disk diffusion susceptibility testing on BCYE of the causative pathogen revealed zone diameters of inhibition of the clinical isolate exceeding 50 mm, indicating high susceptibility to this antibiotic combination. The therapeutic failure of amoxicillin-clavulanic acid should stimulate further reports and studies on the efficacy against legionellosis of this drug and similar beta-lactam inhibitor combinations as well as other beta-lactamase-stable beta-lactams.

show abstract

Bactericidal effects of amoxyciffin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat

Cited by 14 publications

References 0 publications

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp

Bactericidal effects of ticarcillin-clavulanic acid against Legionella pneumophila pneumonia in immunocompromised weanling rats

FatalLegionella pneumophila pneumonia: Treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy

Contact Info

Product

Resources

About